Skip to main content

Innovent, Lilly Co-developed Tyvyt Gets China's NMPA Approval For CHL

China-based Innovent Biologics, Inc. and Eli Lilly and Co. ( LLY ) announced Friday that their co-developed Tyvyt, a fully human anti-PD-1 therapeutic monoclonal antibody, has been granted approval for market authorization by the National Medical Products Administration or NMPA of China.
https://www.nasdaq.com/article/innovent-lilly-codeveloped-tyvyt-gets-chinas-nmpa-approval-for-chl-20181227-00038

No Comments yet!

Your Email address will not be published.

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2022 Esophageal Cancer Education Foundation- by domino